GLP-1 drug interactions: what your prescriber should check

If you take other medications alongside a GLP-1 receptor agonist, your prescriber needs to evaluate potential drug interactions before you start treatment and again at every dose escalation. GLP-1 drugs work partly by slowing gastric emptying — the rate at which food and orally ingested substances move from your stomach into your small intestine. That mechanism, while therapeutically useful for appetite and blood sugar control, can meaningfully alter the absorption kinetics of co-administered oral medications. The clinical significance ranges from negligible to potentially dangerous, depending on the drug involved.

This article reviews the pharmacokinetic interaction data from prescribing information and published studies for the most commonly affected drug classes. It is not a substitute for your prescriber reviewing your specific medication list, but it gives you the knowledge to ask the right questions.

Why gastric emptying matters for drug absorption

Most oral medications are absorbed in the small intestine, not the stomach. The rate at which a pill leaves the stomach (gastric emptying) determines how quickly it reaches the absorption site and achieves peak blood levels (Cmax). Delayed gastric emptying can reduce Cmax — meaning the drug hits a lower peak — while sometimes also delaying the time to reach that peak (Tmax). For some drugs, a lower or delayed Cmax is clinically irrelevant. For drugs with narrow therapeutic windows — where small changes in blood levels mean the difference between efficacy and toxicity — even modest absorption changes can matter.

Both semaglutide and tirzepatide delay gastric emptying, but the effect is most pronounced in the early weeks of treatment and at higher doses. The degree of delay varies between the two drugs and is relevant context for understanding the interaction profiles below.

Oral contraceptives: tirzepatide requires specific action

This is the interaction with the most actionable clinical guidance. In pharmacokinetic studies with tirzepatide, co-administration with a combined oral contraceptive containing ethinylestradiol and norgestimate produced clinically meaningful reductions in hormone exposure. Specifically, tirzepatide reduced ethinylestradiol Cmax by 59% and AUC by 21%, and reduced the active metabolite norelgestromin Cmax by 55%. These reductions are large enough to potentially compromise contraceptive efficacy.

The tirzepatide prescribing information recommends that patients using combined oral contraceptives either switch to a non-oral contraceptive method (such as an IUD, implant, or injection) or add a barrier method (such as condoms) for 4 weeks after initiation and for 4 weeks after each dose increase. This is not a general warning — it is specific, data-driven guidance. Once a patient is on a stable maintenance dose and gastric emptying has partially normalized, the interaction may lessen, but the prescribing information does not give an all-clear to remove the backup method based on time alone.

By contrast, semaglutide pharmacokinetic studies with combined oral contraceptives did not show clinically meaningful changes in hormone exposure. The Wegovy prescribing information does not include a recommendation for backup contraception. However, given that semaglutide does delay gastric emptying, some clinicians still counsel patients about the theoretical risk, particularly at higher doses.

Levothyroxine: check your thyroid levels after starting

Levothyroxine (Synthroid, Levoxyl, and generics) is a narrow therapeutic index drug that millions of hypothyroid patients take daily. It requires an empty stomach and consistent absorption conditions for stable thyroid hormone levels. Oral semaglutide pharmacokinetic studies showed significant changes in levothyroxine exposure, which is clinically relevant because even small deviations in thyroid hormone levels can cause symptoms.

The practical guidance is straightforward: if you take levothyroxine and start any GLP-1 medication, your prescriber should recheck your TSH level 6 to 8 weeks after starting treatment and again 6 to 8 weeks after each dose increase. Dose adjustments to the levothyroxine may be necessary. Continue to take levothyroxine on an empty stomach as directed — the GLP-1 interaction adds a variable on top of the existing absorption requirements, it does not replace them.

Injectable semaglutide and tirzepatide may have a smaller effect on levothyroxine absorption compared to the oral formulation, since the GLP-1 drug itself is not passing through the GI tract. However, the gastric emptying delay still exists with injectables, and monitoring is still recommended.

Warfarin: monitor INR but major changes are uncommon

Warfarin is another narrow therapeutic index drug where absorption changes could theoretically shift anticoagulation levels into dangerous territory (either increased bleeding risk or reduced protection against clots). Pharmacokinetic studies with semaglutide showed a delayed Tmax for warfarin, meaning it takes longer to reach peak blood levels. However, the overall exposure (AUC) and peak concentration (Cmax) were generally preserved.

In clinical practice, this means warfarin is unlikely to require dose changes solely because of GLP-1 initiation, but INR monitoring is still recommended — particularly during the first few weeks of treatment and after dose escalations. The delayed Tmax could transiently affect the time course of anticoagulation, and patients on warfarin are already accustomed to regular INR checks. Simply ensure your anticoagulation clinic or prescriber knows you are starting a GLP-1 medication.

Insulin and sulfonylureas: real hypoglycemia risk

This is probably the most clinically important interaction in terms of immediate patient safety. GLP-1 receptor agonists enhance insulin secretion in a glucose-dependent manner and improve insulin sensitivity. When combined with exogenous insulin or insulin secretagogues like sulfonylureas (glimepiride, glipizide, glyburide), the risk of hypoglycemia increases significantly.

The prescribing information for both semaglutide and tirzepatide explicitly warns about this combination and recommends considering a reduction in the dose of insulin or sulfonylurea when initiating GLP-1 therapy. The magnitude of the required reduction varies — some patients need a 20% reduction in basal insulin from day one, while others can be monitored and adjusted reactively. This decision depends on the patient's baseline glucose control, the specific insulin regimen, and the GLP-1 dose being started.

If you take insulin or a sulfonylurea and are starting a GLP-1 drug, this interaction should be discussed explicitly with your prescriber before the first dose. You should also have a clear plan for hypoglycemia management, including knowing the symptoms (shakiness, sweating, confusion, rapid heartbeat) and having glucose tablets or a fast-acting carbohydrate source available.

Acetaminophen: delayed peak but same total exposure

Acetaminophen (paracetamol, Tylenol) is frequently used as a probe drug in pharmacokinetic studies because its absorption is well characterized and sensitive to changes in gastric emptying. Studies with semaglutide showed a delayed Tmax for acetaminophen by approximately 1 hour, meaning it takes longer for pain relief to kick in. However, the Cmax and AUC were preserved, meaning the total amount of drug absorbed and the peak level reached were not meaningfully changed.

The clinical implication is minor: if you take acetaminophen for a headache while on a GLP-1 medication, it may take slightly longer to work but will still be effective. This does not require dose adjustment or avoidance. However, the acetaminophen finding is a useful illustration of the general principle — delayed gastric emptying shifts the timing of absorption, which matters more for some drugs than others.

Other medications: what to flag for your prescriber

Beyond the specific drugs studied in formal pharmacokinetic trials, the gastric emptying mechanism of GLP-1 drugs means any oral medication could theoretically be affected. Drugs that deserve particular attention include:

• Antibiotics with time-dependent efficacy: absorption delays could alter the pharmacokinetic profile. Discuss with your prescriber if you need a course of oral antibiotics.

• Seizure medications (e.g., phenytoin, carbamazepine, valproate): many have narrow therapeutic windows and require consistent blood levels.

• Immunosuppressants (e.g., tacrolimus, cyclosporine): narrow therapeutic index drugs where absorption variability can lead to rejection episodes or toxicity.

• Oral diabetes medications beyond sulfonylureas: metformin absorption may be delayed but is generally clinically insignificant. SGLT2 inhibitors are less studied in combination.

• Psychiatric medications: SSRIs, SNRIs, and antipsychotics could have altered absorption profiles, though clinical significance is not well established for most.

Summary: drug interaction reference table

The following table summarizes the key drug interactions with GLP-1 receptor agonists, the clinical significance of each, and the recommended action. Use this as a starting point for conversations with your prescriber — not as a substitute for individualized medical advice.

Practical steps: what to do before your first dose

Drug interactions with GLP-1 medications are manageable, but only if your prescriber has a complete picture of what you take. Here are the steps to take before starting treatment:

• Bring a complete medication list to your intake appointment — include prescription drugs, over-the-counter medications, supplements, and herbal products.

• Flag any drug with a narrow therapeutic window (levothyroxine, warfarin, seizure medications, immunosuppressants) and ask your prescriber about monitoring schedules.

• If you take combined oral contraceptives and are starting tirzepatide, discuss switching to a non-oral method or adding a barrier method immediately.

• If you take insulin or a sulfonylurea, ask specifically about dose adjustment at GLP-1 initiation — do not wait until hypoglycemia occurs.

• Ask your prescriber about the monitoring plan: which labs will be checked, at what intervals, and what symptoms should prompt you to call.

• Keep a record of any changes in the effectiveness of your other medications after starting a GLP-1 drug. Report persistent changes to your prescriber.

Telehealth providers vary in how thoroughly they screen for drug interactions. A responsible program will ask about all current medications during intake and will have a pharmacist or prescriber review the list for interactions before issuing a GLP-1 prescription. If a provider does not ask about your other medications, that is a significant red flag.